Conclusions
schizophrenia
DISEASE
In conclusion, based on a large multicenter, open-label, randomized trial of 964 patients with schizophrenia receiving monotherapy with olanzapine, risperidone, amisulpride, and aripiprazole, this study confirmed that early non-response to antipsychotics is a predictor of later non-response. Moreover, antipsychotic non-response at week 8 can be predicted as early as week 2, but the optimum predictive cut-offs should be determined based on the antipsychotic type and baseline severity. Moreover, when non-response at week 4 was used as a predictor, the most appropriate predictive cut-off was consistently observed regardless of antipsychotic types or disease severity.